Vanguard Personalized Indexing Management LLC Raises Stock Position in Medpace Holdings, Inc. $MEDP

Vanguard Personalized Indexing Management LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 23.4% during the 3rd quarter, Holdings Channel.com reports. The fund owned 4,625 shares of the company’s stock after acquiring an additional 876 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Medpace were worth $2,379,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Clarkston Capital Partners LLC bought a new position in shares of Medpace during the second quarter worth $40,569,000. Brighton Jones LLC lifted its stake in Medpace by 160.4% in the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after purchasing an additional 2,501 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Medpace by 150.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after purchasing an additional 9,117 shares during the last quarter. Baillie Gifford & Co. grew its position in shares of Medpace by 12.0% during the third quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock valued at $300,679,000 after purchasing an additional 62,503 shares in the last quarter. Finally, Jump Financial LLC bought a new stake in shares of Medpace in the second quarter worth about $15,729,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

MEDP has been the subject of a number of research reports. Barclays increased their price target on Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a research note on Monday, December 15th. Truist Financial set a $555.00 target price on shares of Medpace in a report on Monday, October 27th. BMO Capital Markets started coverage on shares of Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price target on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Medpace in a research report on Friday, October 31st. Finally, Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Medpace has an average rating of “Reduce” and a consensus target price of $491.27.

Insider Activity at Medpace

In related news, CEO August J. Troendle sold 59,025 shares of the stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total value of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This represents a 7.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the completion of the sale, the vice president directly owned 27,500 shares of the company’s stock, valued at approximately $16,751,625. The trade was a 42.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 341,695 shares of company stock worth $205,718,239. Insiders own 20.30% of the company’s stock.

Medpace Stock Down 0.8%

NASDAQ MEDP opened at $593.07 on Friday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $628.92. The firm has a market capitalization of $16.71 billion, a price-to-earnings ratio of 41.47, a PEG ratio of 2.01 and a beta of 1.43. The company has a fifty day moving average of $584.47 and a two-hundred day moving average of $527.52.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.